Effectiveness of Atypical Antipsychotic Medication for Outpatients With Anorexia Nervosa
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT00685334|
Recruitment Status : Completed
First Posted : May 28, 2008
Results First Posted : February 4, 2010
Last Update Posted : October 29, 2013
|Condition or disease||Intervention/treatment||Phase|
|Eating Disorders||Drug: Olanzapine Drug: Aripiprazole||Phase 4|
Anorexia nervosa (AN) is a disease of disordered eating that is characterized by self-starvation, often leading to extreme weight loss and difficulty maintaining a normal weight. Symptoms and behaviors of AN may include distorted body image, obsessive exercise, lack of menstruation among women, binge and purge eating behaviors, and intense fear of weight gain. Furthermore, people with AN are at a high risk of other mental disorders, such as depression and anxiety, and medical complications, such as organ damage, heart failure, and osteoporosis. Current treatments for AN include nutrition counseling, psychotherapy, and medication. Previous studies have suggested that certain medications usually used to treat schizophrenia, also known as atypical antipsychotic drugs, may be helpful in treating people with AN. Specifically, the atypical antipsychotic medications olanzapine and aripiprazole may be effective in improving overall symptoms of AN and in restoring weight to normal levels. This study will compare the effectiveness of olanzapine and aripiprazole in treating people with AN.
Participation in this study will last 12 weeks. All participants will first undergo baseline assessments that will include questionnaires and interviews about AN symptoms, a physical exam, vital sign measurements, an electrocardiograph (EKG), and a blood draw. Participants will then be assigned randomly to 12 weeks of treatment with daily olanzapine or aripiprazole. Participants will meet with a study doctor weekly over the 12 weeks of treatment. During these visits, the study doctor will monitor participants' progress, medication dosage, vital signs, and side effects. In addition, participants will undergo repeat blood draws every 4 weeks and repeat questionnaires every month of the treatment period. Upon completing the 12 weeks of treatment, participants will repeat most baseline assessments.
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||22 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||None (Open Label)|
|Official Title:||Atypical Antipsychotic Medication for Outpatients With Anorexia Nervosa|
|Study Start Date :||November 2003|
|Actual Primary Completion Date :||September 2006|
|Actual Study Completion Date :||September 2006|
Participants will take olanzapine
Participants will take olanzapine daily for 12 weeks.
Other Name: zyprexa
Active Comparator: 2
Participants will take aripiprazole
Participants will take aripiprazole daily for 12 weeks.
Other Name: Abilify
- Change From Baseline in Weight (Lbs.) at 12 Weeks [ Time Frame: baseline and 12 weeks ]This study looked at change in weight before and after medication use.
- Tolerability [ Time Frame: Measured at Week 12 ]This study addressed the benefits, tolerability, acceptability, safety, and appropriate dosage of olanzapine and aripiprazole, as determined by clinical evaluation and self report. The outcome measure reported here is the number of patients who did not experience untoward side effects while taking the medication.
- Medication Side Effects [ Time Frame: Measured at Week 12 ]Common side effects include sedation, dizziness, and headache for patients on olanzapine and akathisia, anxiety, dizziness and blurred vision for patients receiving aripriprazole.
- Treatment Compliance [ Time Frame: Measured at Week 12 ]Total number of randomized patients that completed the full 12 weeks of treatment.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00685334
|United States, New York|
|New York State Psychiatric Institute|
|New York, New York, United States, 10032|
|Toronto General Hospital|
|Toronto, Ontario, Canada, M5G2C4|
|Principal Investigator:||Evelyn Attia, MD||New York State Psychiatric Institute at Columbia University Medical Center|